TTX MC 138
Alternative Names: TTX-MC-138Latest Information Update: 10 Feb 2026
At a glance
- Originator TransCode Therapeutics
- Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
- Mechanism of Action Cell death stimulants; Gene silencing; MicroRNA inhibitors
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Colorectal cancer; Glioblastoma; Osteosarcoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Unspecified